Key result
Clazosentan reduces moderate-to-severe cerebral vasospasm ~46% compared with placebo.
Why the study?
Cerebral vasospasm after aneurysmal subarachnoid hemorrhage causes delayed cerebral ischemia and secondary brain damage. This review evaluated the efficacy and outcomes of clazosentan, an endothelin A receptor antagonist targeting cerebral vasospasm, in post-aSAH patients.
Does clazosentan reduce cerebral vasospasm and improve clinical outcomes in post-aneurysmal subarachnoid hemorrhage patients compared with placebo?
Meta-Analysis (n=2,635)
Does clazosentan reduce cerebral vasospasm and improve clinical outcomes in post-aneurysmal subarachnoid hemorrhage patients compared with placebo?
In patients with aneurysmal subarachnoid hemorrhage, clazosentan reduces moderate-to-severe cerebral vasospasm and vasospasm-related mortality but substantially increases the risks of pulmonary complications, hypotension, and anemia.
Answers are grounded in this paper and cite their sources.
Clazosentan may warrant use for vasospasm prevention despite added complications; confirms efficacy across six randomized trials in aneurysmal subarachnoid hemorrhage.
Introduction: Cerebral vasospasm is a mechanism after aneurysmal subarachnoid hemorrhage (aSAH), which occurs due to the blood vessel response from aneurysm rupture. This condition leads into delayed cerebral ischemia (DCI) or secondary brain damage due to decreased blood flow to brain tissue. Clazosentan is an endothelin A receptor antagonist that specifically targets cerebral vasospasm after aSAH. This study aimed to discuss the efficacy and outcomes of clazosentan therapy as an anti-vasospasm agent in post-aSAH patients. Methods: A literature search and data processing were conducted from May to September 2025 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Bias assessment was performed using the RoB 2 guidelines for randomized controlled trials. Data analysis was performed using Cochrane Revman 5.4, covering moderate to severe cerebral vasospasm, treatment outcomes based on the Glasgow Outcome Scale (GOSE) and modified Rankin Scale (mRS) scores, vasospasm-related mortality, and complications (pulmonary, hypotension, and anemia). Results: Six RCTs involving 2,635 patients were included in this meta-analysis. Clazosentan significantly reduced moderate to severe cerebral vasospasm (RR 0.54, [95% CI 0.46–0.62], p <0.00001) compared with placebo. Clazosentan 5 mg/hour (RR 0.58 [95% CI 0.40–0.95] p <0.03) reduced the risk of adverse treatment outcomes (GOSE ≤ 4) compared with placebo. Clazosentan significantly reduced the risk of death from cerebral vasospasm (RR 0.40, [95% CI 0.28–0.49], p <0.00001). Based on treatment side effects, clozasentan significantly increased the risk of pulmonary complications (RR 1.81, [95% CI 1.58 – 2.08], p < 0.00001), hypotension (RR 2.33, 95% CI 1.64 – 3.33, p < 0.0001), and anemia (RR 1.96, [95% CI 1.24 – 3.11], p < 0.00001) compared to placebo. Conclusions: Clazosentan can significantly reduce cerebral vasospasm and death from vasospasm. However, treatment side effects, long-term outcomes, and eligibility criteria for clazosentan require further research to reduce morbidity and mortality from aSAH.
No takes yet. Share an insight, caveat, or question.
Putri et al. (2026) conducted a meta-analysis in Aneurysmal subarachnoid hemorrhage (aSAH) (n=2,635). Clazosentan vs. Placebo was evaluated on Moderate to severe cerebral vasospasm (RR 0.54, 95% CI 0.46-0.62, p=<0.00001). Clazosentan reduced moderate to severe cerebral vasospasm and vasospasm-related death compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: